SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for HRMY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
March 31, 2026 64.20M
December 31, 2025 86.74M
September 30, 2025 59.36M
June 30, 2025 64.00M
March 31, 2025 61.95M
December 31, 2024 56.46M
September 30, 2024 56.16M
June 30, 2024 55.73M
March 31, 2024 52.91M
December 31, 2023 54.76M
September 30, 2023 45.96M
June 30, 2023 47.34M
March 31, 2023 44.63M
December 31, 2022 43.72M
September 30, 2022 41.80M
Date Value
June 30, 2022 42.32M
March 31, 2022 35.46M
December 31, 2021 37.31M
September 30, 2021 33.34M
June 30, 2021 31.32M
March 31, 2021 30.05M
December 31, 2020 30.99M
September 30, 2020 23.11M
June 30, 2020 18.92M
March 31, 2020 22.54M
December 31, 2019 0.00
September 30, 2019 0.00
June 30, 2019 14.27M
March 31, 2019 10.15M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 73.66M
Johnson & Johnson 6.034B
Indivior Pharmaceuticals, Inc. 124.00M
Royalty Pharma Plc 159.49M
Corcept Therapeutics, Inc. 145.36M